Eertink, Jakoba J. http://orcid.org/0000-0002-6094-0016
van de Brug, Tim http://orcid.org/0000-0003-3541-9111
Wiegers, Sanne E. http://orcid.org/0000-0003-3698-8121
Zwezerijnen, Gerben J. C. http://orcid.org/0000-0002-9571-9362
Pfaehler, Elisabeth A. G. http://orcid.org/0000-0002-6160-3011
Lugtenburg, Pieternella J. http://orcid.org/0000-0002-6735-8651
van der Holt, Bronno
de Vet, Henrica C. W. http://orcid.org/0000-0002-5454-2804
Hoekstra, Otto S. http://orcid.org/0000-0003-0767-2734
Boellaard, Ronald http://orcid.org/0000-0002-0313-5686
Zijlstra, Josée M. http://orcid.org/0000-0003-1074-5922
Funding for this research was provided by:
KWF Kankerbestrijding (#VU 2018-11648)
Article History
Received: 7 April 2021
Accepted: 17 June 2021
First Online: 18 August 2021
Declarations
:
: The HOVON-84 study was approved by the institutional review board of the Erasmus MC (2007–055) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All individual participants included in the HOVON-84 study gave written informed consent to participate in the study.
: Not applicable.
: J.J.E., T.v.d.B., S.E.W., G.J.C.Z., E.A.G.P., B.v.d.H., H.C.W.d.V., O.S.H., and R.B. declare no competing financial interests. P.J.L. received research funding from Takeda, Servier, and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, and Incyte. J.M.Z. received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, and Roche.